Comparative Pharmacology
Head-to-head clinical analysis: CITANEST PLAIN versus GLYDO.
Head-to-head clinical analysis: CITANEST PLAIN versus GLYDO.
CITANEST PLAIN vs GLYDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks sodium channels, inhibiting nerve impulse conduction.
GLYDO (lidocaine) is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Prilocaine 1-2% solution: local infiltration, 1-20 mL of 1-2% (10-400 mg); nerve block, 10-40 mL of 1-2% (100-800 mg); epidural, 15-30 mL of 2% (300-600 mg). Maximum dose: 8 mg/kg (600 mg) as single dose, not to exceed 600 mg without epinephrine.
For anesthesia: 1-5% solution, 0.5-5 mg/kg IV or 2.5-15 mg intrathecally; for antiarrhythmic: 1-1.5 mg/kg IV bolus then 1-4 mg/min infusion.
None Documented
None Documented
The terminal elimination half-life of prilocaine is approximately 1.5 hours in adults with normal hepatic and renal function. In neonates, the half-life may be prolonged to 3-4 hours due to immature hepatic metabolism. This short half-life supports its use for procedures requiring moderate duration of anesthesia.
Terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged (up to 3-4 hours) due to immature hepatic metabolism.
Prilocaine is metabolized primarily in the liver via amidases, with major metabolites including o-toluidine and N-propylalanine. Approximately 50-70% of the dose is excreted renally as metabolites, with less than 2% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Renal excretion of unchanged drug accounts for approximately 10% of the dose; the remainder is metabolized in the liver to inactive metabolites that are excreted renally. Fecal elimination is negligible (<2%).
Category C
Category C
Local Anesthetic (Amide)
Local Anesthetic (Amide)